CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

A US court just put ownership of CRISPR back in play The CRISPR patents are back in play. Yesterday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle ...

The baby's disease prevented the liver from removing ammonia Half of babies with the disease die in their first week of life The baby has already shown signs of improvement The baby's disease ...

Last August, KJ Muldoon was born with a potentially fatal genetic disorder. Just six months later, he received a Crispr treatment designed just for him. Muldoon has a rare disorder known as CPS1 ...

When CRISPR was first introduced as a gene-editing tool in 2012, the world was in awe of all the possibilities it held — eventually earning its discoverers the Nobel Prize in Chemistry in 2020. Now, ...

The most well-known is CRISPR-Cas9, adapted for human use as the first FDA-approved genetic editing technique. In the past year, researchers at Rockefeller's Laboratory of Bacteriology ...

Now, a first-in-human clinical trial is testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal cancers. The results show encouraging signs of safety ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

CRISPR Therapeutics stock is heavily shorted in the weeks going into earnings The short-sellers are betting against the name in a big way, with more than 20 million shares sold short as of the ...

You can reach Megan on Signal at mmolteni.13. The now 13-year-long legal saga over who invented CRISPR took yet another unexpected turn on Monday, in a ruling that could not only change U.S ...